PMVP — Pmv Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$1.25
-$0.04 (-2.71%)
Pmv Pharmaceuticals Inc (PMVP) is a biotechnology company listed on NASDAQ. It is led by David H. Mack Ph.D., based in 400 Alexander Park Drive, Princeton, NJ, United States, 08540, with about 54 employees. PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Net income was -$59.7M. PMVP currently screens at market cap $58.7M.
On the latest cached filing, PMVP: PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offeri… (8-K 2026-09-01). This PMVP stock page is the analysis view: what changed in the numbers, and why it matters for Pmv Pharmaceuticals Inc.
Use this PMVP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PMVP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PMVP SEC filings page. Lician reads the product cache first so this HTML stays unique to Pmv Pharmaceuticals Inc even when a live quote feed is slow.
What changed in PMVP
8-K · 2026-09-01
PMVP: PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offeri…
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
PMVP Key Statistics
Market Cap
$58.66M
Volume
207,996
Previous Close
$1.30
Day Range
$1.29 – $1.32
P/B Ratio
0.67
EPS
-$1.14
Revenue
$0.00
Net Income
-$58.71M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
54
PMVP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$58.71M | -$68.96M | -$73.32M | -$57.85M |
| EPS (Diluted) | -$1.14 | -$1.44 | -$1.61 | -$1.28 |
Total Assets
$191.29M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$40.88M
Operating Cash Flow
-$51.28M
Free Cash Flow
$0.00
Pmv Pharmaceuticals Inc Company Information
- Co-Founder, CEO, President & Director
- David H. Mack Ph.D.
- Headquarters
- 400 Alexander Park Drive, Princeton, NJ, United States, 08540
- Website
- www.pmvpharma.com
- Phone
- 609 642 6670
- IPO / Founded
- 2020-09-25
- Sector
- Healthcare
- Industry
- Biotechnology